Quelle stratégie thérapeutique devant un cancer du rectum avec métastases hépatiques synchrones

作者: A. Brouquet , S. Benoist

DOI: 10.1007/S11725-012-0377-Y

关键词: MedicineGynecology

摘要: Le cancer du rectum avec metastases hepatiques synchrones regroupe un large eventail de presentations cliniques. Chez les malades ayant synchrones, la strategie therapeutique va dependre site et l’extension tumeur rectum, maladie metastatique hepatique extra-hepatique. Dans majorite des cas ne sont pas resecables dans cette situation, le premier objectif traitement est prolonger survie preserver qualite vie. La prise en charge ces repose grande partie sur chimiotherapie local propose symptomes ou complications lies a primitive. resecables, une visee curative doit etre envisagee nombreuses options peuvent discutees aussi bien ce qui concerne l’administration traitements preoperatoires (radiotherapie, radiochimiotherapie chimiotherapie) que sequence chirurgicale optimale (strategie simultanee chirurgies separees). permettre traiter tous sites tumoraux facon appropriee. bilan pre precis vise notamment identifier tumoral plus menacant traite priorite sans compromettre optimal l’autre tumoral. Compte tenu cliniques therapeutiques proposees, il n’est possible definir attitude standardisee convenant malades. Une discussion pluridisciplinaire debut

参考文章(58)
S. Benoist, K. Pautrat, E. Mitry, P. Rougier, C. Penna, B. Nordlinger, Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. British Journal of Surgery. ,vol. 92, pp. 1155- 1160 ,(2005) , 10.1002/BJS.5060
R Jakobs, J Miola, A Eickhoff, H E Adamek, J F Riemann, Endoscopic laser palliation for rectal cancer-- therapeutic outcome and complications in eighty-three consecutive patients. Zeitschrift Fur Gastroenterologie. ,vol. 40, pp. 551- 556 ,(2002) , 10.1055/S-2002-33414
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Scott Kopetz, George J. Chang, Michael J. Overman, Cathy Eng, Daniel J. Sargent, David W. Larson, Axel Grothey, Jean-Nicolas Vauthey, David M. Nagorney, Robert R. McWilliams, Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy Journal of Clinical Oncology. ,vol. 27, pp. 3677- 3683 ,(2009) , 10.1200/JCO.2008.20.5278
Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinò, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, Gianluca Masi, Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest Journal of Clinical Oncology. ,vol. 25, pp. 1670- 1676 ,(2007) , 10.1200/JCO.2006.09.0928
Larissa K.F. Temple, Lillian Hsieh, W. Douglas Wong, Leonard Saltz, Deborah Schrag, Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3475- 3484 ,(2004) , 10.1200/JCO.2004.10.218
R. J. Baigrie, A. R. Berry, Management of advanced rectal cancer British Journal of Surgery. ,vol. 81, pp. 343- 352 ,(2005) , 10.1002/BJS.1800810307
Yu Jo Chua, Yolanda Barbachano, David Cunningham, Jacqui R Oates, Gina Brown, Andrew Wotherspoon, Diana Tait, Alison Massey, Niall C Tebbutt, Ian Chau, Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial Lancet Oncology. ,vol. 11, pp. 241- 248 ,(2010) , 10.1016/S1470-2045(09)70381-X
NC Tebbutt, AR Norman, D Cunningham, ME Hill, D Tait, J Oates, S Livingston, J Andreyev, Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases Gut. ,vol. 52, pp. 568- 573 ,(2003) , 10.1136/GUT.52.4.568
A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, A. Bonetti, Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer Journal of Clinical Oncology. ,vol. 18, pp. 2938- 2947 ,(2000) , 10.1200/JCO.2000.18.16.2938